glp-1 drugs impact on energy levels 2.0: Where the Next Wave of Value Will Be Created GLP-1 Drugs and the Physiology

Science 313 , 670673 (2006)

Doctor Discussion Bring this list of questions to your next appointment to guide the conversation: Am I a candidate for a GLP-1 or dual GIP/GLP-1 agonist, considering my personal and family medical history

For example, patients taking Wegovy (semaglutide 2.4 mg) achieved an average weight loss of 14.9% after 68 weeks when paired with lifestyle changes

doi: 10.1016/j.bbr.2019.111932 [DOI] [PubMed] [Google Scholar] 85

The gut microbiota and Alzheimers disease

The medicine is being marketed under the brand name Lirafit after receiving approval from the medicine Controller General of India (DCGI)